Modality
mAb
MOA
BETi
Target
SOS1
Pathway
Complement
PompeRA
Development Pipeline
Preclinical
Jan 2017
→ Sep 2029
PreclinicalCurrent
NCT06150634
742 pts·Pompe
2017-04→2029-09·Completed
NCT06164987
1,405 pts·RA
2017-01→TBD·Completed
2,147 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-043.4y awayInterim· Pompe
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2029-09-04 · 3.4y away
Pompe
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06150634 | Preclinical | Pompe | Completed | 742 | MRD |
| NCT06164987 | Preclinical | RA | Completed | 1405 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 |